Jonathan Weiss / Shutterstock.com
The US Court of Appeals for the Federal Circuit affirmed a series of Patent Trial and Appeal Board (PTAB) inter partes reviews (IPRs), which upheld a patent owned by Eli Lilly late last week.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Eli Lilly, PTAB, Alimta, chemotherapy, Neptune Generics, Mylan, Fresenius Kabi, US Court of Appeals for the Federal Circuit, IPRs
